Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.
Aristotelis Bamias, MD
Advertisement
Articles by Aristotelis Bamias, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5